Joshua Ranum, MD
Internal Medicine · Hettinger, NDNPI 1609035120
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $607 of the $782 with a category attached, or 77.6%. It is spread thinly across 12 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $214, 2.6 times the $84 reported in 2019.
Across 36 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$180
- Amgen$175
- Boehringer Ingelheim$171
- AbbVie$74
- Novartis$39
- Bayer$27
- plus $115 from 6 others
What the payments were for
- Consulting fees$17522%
- Food & beverage$60778%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 9 | $180 |
| Amgen | 1 | $175 |
| Boehringer Ingelheim | 10 | $171 |
| AbbVie | 4 | $74 |
| Novartis | 2 | $39 |
| Bayer | 2 | $27 |
| Merck | 2 | $26 |
| GSK | 2 | $24 |
| Medtronic | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$782 in reported general payments places this provider in the 80th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $229,330 |
| JardianceEmpagliflozin | 173 | $150,696 |
| Avonex (4 Pack)Interferon Beta-1a | 14 | $114,120 |
| MounjaroTirzepatide | 64 | $71,686 |
| XareltoRivaroxaban | 77 | $60,531 |
| OzempicSemaglutide | 60 | $58,910 |
| TrulicityDulaglutide | 53 | $56,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $52,820 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,020 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 53 | $48,991 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $34,238 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $26,593 |
| FarxigaDapagliflozin Propanediol | 29 | $24,377 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $19,803 |
| RexultiBrexpiprazole | 26 | $18,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $171 | $167,202185 claims |
| Lilly USA, LLCMounjaro, Trulicity | $180 | $127,942117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $24 | $84,843140 claims |
| Johnson & JohnsonXarelto | $17 | $60,53177 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $13 | $32,77342 claims |
| MerckJanumet Xr, Dulera | $26 | $22,89940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Hettinger
- Brian WilloughbyHettinger$1K
- Michael LillestolFargo$18K
- Khalin DendyBismarck$10K
- Bruce OlinDickinson$8K
- Gene SchwartzTrenton$6K
- Stephanie CanhamBismarck$4K
- Radu RautaBismarck$3K
- Donald GrenzBismarck$3K
- Julia SchwartzBismarck$3K
- Amanda BlanchardBismarck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.